Announcements Trials
Browse Landscape

Phase

Phase 2 19Phase 3 15Phase 1 9Phase 2/3 5Phase EARLY_PHASE1 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 1

Interventions

pembrolizumab 3Nivolumab 3Magnetic Resonance Spectroscopy 3Radiotherapy 2Ipilimumab 2Fluorodeoxyglucose F18 2Cyclophosphamide 2sugemalimab 1semaglutide 1sacituzumab govitecan 1prednylidene 1pirtobrutinib 1paricalcitol 1mirdametinib 1gadobutrol 1fludarabine phosphate 1fludarabine 1erdafitinib 1enfortumab vedotin 1deltacortene 1daratumumab 1brivaracetam 1brexucabtagene autoleucel 1azeliragon 1avelumab 1alovudine 1acalabrutinib 1Watchful Waiting 1Vorinostat 1Vincristine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Immunoglobulin G × 30 days × Clear all
NCT02210117 2026-06-01

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
104 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡